BINHUI BIOPHARM

Binhui Biopharmaceutical Co., Ltd. was established in 2010 and has been deeply engaged in the field of oncolytic virus research for over a decade, becoming a leading Chinese enterprise in the independent research and development of oncolytic virus drugs. The company has built an oncolytic virus (oHSV2) technology platform, and its first developed product, OH2 injection, has obtained three clinical approvals for both monotherapy and combination therapy. It is the only oncolytic virus product in China that has entered Phase II clinical trials for multiple indications with both monotherapy and combination therapy, achieving positive data. Based on the leading oHSV2 oncolytic immunotherapy platform, in addition to a rich pipeline of oncolytic virus products, the company is also actively developing viral vector vaccines, recombinant protein vaccines, and nucleic acid vaccines, expanding its technological platform across multiple fields.The company owns GMP-standard clean production workshops and has established FDA and NMPA-recognized production processes. The integration of production and research fully meets the needs of clinical research and industrialization progress.The company has built a top-tier international R&D team and management team, gaining favor from well-known venture capital and industry funds such as Dawan Venture Capital, Longpan Investment, Lepu Medical, Share Investment, CICC Capital, Vertex Investment, and Qianhai Mother Fund, providing strong support for the company’s development.